Skip to main content

Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection Images

Generic Name: ranibizumab

This medication has been identified as Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection. It is supplied by Coherus BioSciences, Inc.

Cimerli is used in the treatment of Macular Edema Following Retinal Vein Occlusion ; Macular Degeneration; Diabetic Retinopathy; Macular Edema; Myopic Choroidal Neovascularization and belongs to the drug class anti-angiogenic ophthalmic agents. Risk cannot be ruled out during pregnancy. Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection medicine

Cimerli

Generic Name
ranibizumab
Strength
0.3 mg/0.05 mL (6 mg/mL) intravitreal injection
Availability
Prescription only
Drug Class
Anti-angiogenic ophthalmic agents
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Coherus BioSciences, Inc.
National Drug Code (NDC)
70114-0440

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.